title: Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study.
abstract: OBJECTIVE
  Erectile dysfunction (ED) is a common problem for elderly males. Higher serum lipid levels have important role in the pathogenesis, and in this prospective randomized trial, it is aimed to identify the effect of atorvastatin on erectile functions in comparison with regular tadalafil use.
  
  
  METHODS
  120 patients with a minimum 3-months history of moderate-to-severe ED were involved. The patients were randomized to receive atorvastatin 10 mg/day, tadalafil 20 mg 3 times/week or no medication. Baseline serum testosterone, lipid levels IEEF and NPT test were performed and repeated after 3 months of treatment, and the 3 groups were compared.
  
  
  RESULTS
  Mean age of the whole population was 56 years (31-70). The 3 groups were well balanced for the baseline characteristics. Mean improvement of IIEF score was significantly higher in tadalafil group compared to atorvastatin (P = 0.01) and control group (P = 0.0001). Also atorvastatin showed significantly better improvement compared to control group (P = 0.001). Positive NPT test results in tadalafil group was significantly higher than atorvastatin group (25/40 (62.5%) vs. 16/41 (39%), P = 0.003) and compared to control group (25/40 (62.5%) vs. 3/39 (7.6%), P = 0.0001). At the same time, the difference between group 1 and group 3 was statistically significant (P = 0.001).
  
  
  CONCLUSIONS
  Tadalafil 20 mg three times/week shows better results than 10 mg atorvastatin daily. Atorvastatin alone seems to improve EF compared to not using any medication, and this significance is more prominent in patients with supranormal serum lipid levels. Further studies with subgroups of different serum lipid levels should be conducted.
authors.affiliation: Department of Urology, Ankara University School of Medicine, Adnan Saygun Caddesi, Altındağ, Ankara, Turkey. migokce@yahoo.com
authors.forename: Mehmet İlker
authors.initials: Mİ
authors.lastname: Gokce
authors.forename: Ömer
authors.initials: Ö
authors.lastname: Gülpınar
authors.forename: Erdem
authors.initials: E
authors.lastname: Öztürk
authors.forename: Sadi
authors.initials: S
authors.lastname: Güleç
authors.forename: Önder
authors.initials: Ö
authors.lastname: Yaman
mesh_terms: D000328:Adult; D000368:Aged; D000069059:Atorvastatin; D002243:Carbolines / Q000494:pharmacology / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010410:Penile Erection / Q000187:drug effects; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D016037:Single-Blind Method; D000068581:Tadalafil
chemical_list: D002243:Carbolines; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D058986:Phosphodiesterase 5 Inhibitors; D011758:Pyrroles; D000068581:Tadalafil; D000069059:Atorvastatin